Beam Therapeutics
BEAM
20.90
-0.04
-0.19%
Beam Therapeutics
US · BEAM
#2614 by market cap
Listed 2020
20.90
-0.04
-0.19%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80Market Newswire · 2026/11/11
-
Rating change
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $41Market Newswire · 2026/11/4
-
Citi Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $68Market Newswire · 2026/11/11
-
Rating change
Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.Dow Jones · 2026/10/16
-
These Analysts Think Beam Therapeutics Inc.'s (NASDAQ:BEAM) Sales Are Under ThreatSimply Wall St · 2026/11/5
-
Rating change
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $43Market Newswire · 2026/10/28
-
Rating change
Maxim Group Maintains Beam Global(BEEM.US) With Buy Rating, Maintains Target Price $3Market Newswire · 2026/10/21
-
Rating change
Evercore Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/10/29
-
Company notice
Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.SEC · 2026/10/17
-
Rating change
Jefferies Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $49Market Newswire · 2026/11/4
-
CCORF Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $78Market Newswire · 2026/11/11
-
Company notice
Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.SEC · 2026/4/7
-
Rating change
CCORF Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $79Market Newswire · 2026/10/29
-
Rating change
Guggenheim Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $51Market Newswire · 2026/11/5
-
Company notice
Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.SEC · 2026/4/2
-
Company notice
4: Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.SEC · 2026/7/2
-
CCORF Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $78Market Newswire · 2026/11/4
-
Rating change
RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Raises Target Price to $26Market Newswire · 2026/11/4
-
Company notice
Okabe: Regarding the release of the "Slab Dandol" side‑hanging hardware for main joists and the "Sokoukeitai" bottom support for beam formwork.JPX · 2026/10/5
-
Rating change
Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $33Market Newswire · 2026/11/11
-
Rating change
Freedom Capital Markets Downgrades Beam Global(BEEM.US) to Hold Rating, Maintains Target Price $1.5Market Newswire · 2026/8/26
-
Rating change
Maxim Group Maintains Beam Global(BEEM.US) With Buy Rating, Cuts Target Price to $3Market Newswire · 2026/8/22
-
Rating change
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/9/9
-
Rating change
J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $44Market Newswire · 2026/8/7
-
Rating change
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price TargetBenzinga · 2026/10/15
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:41 · For reference only, not investment advice and not tailored to your situation.
Beam Therapeutics discussion 0 comments